FLUTICASONE ELLIPTA 100 MCG INH NADAC Price (Updated Weekly)

How pharmacies use NADAC pricing for FLUTICASONE ELLIPTA 100 MCG INH

NADAC represents the average invoice cost pharmacies pay for FLUTICASONE ELLIPTA 100 MCG INH, based on a monthly survey of retail community pharmacies conducted by CMS. Because the data is sourced directly from real pharmacy invoices — not manufacturer list prices like WAC or AWP — it offers the most accurate view of true acquisition cost for FLUTICASONE ELLIPTA 100 MCG INH.

Independent pharmacies use the FLUTICASONE ELLIPTA 100 MCG INH NADAC price to evaluate whether reimbursement from Medicaid, Medicare Part D, and commercial PBMs is in line with the national benchmark. When the ingredient-cost reimbursement falls below NADAC, the claim is paying below the NADAC benchmark. That is a warning sign worth reviewing — but it does not by itself mean the pharmacy lost money. Actual acquisition margin depends on what that pharmacy really paid its wholesaler (which can be above or below NADAC) and on the total payment received, including any dispensing fee. Overall profitability also depends on labor, rent, and other operating expenses. Tracking weekly NADAC updates for FLUTICASONE ELLIPTA 100 MCG INH helps owners spot below-benchmark claims early and raise them with payers.

NADAC pricing for FLUTICASONE ELLIPTA 100 MCG INH updates every Wednesday. Pharmacies that monitor these changes can renegotiate wholesaler contracts when costs spike, adjust cash-pay pricing, and build stronger cases when auditing PBM reimbursement against real acquisition costs.